BioSpace News Archive

The $50 million Innovation and Research Park on the campus of Rosalind Franklin University of Medicine and Science secured its first occupant this month when Inspirotec, Inc. executed a five-year license agreement.

- Varian (NYSE: VAR) today announced its fourth quarter of fiscal year 2020 earnings release date. The Company will report results for the fourth quarter of fiscal year 2020 after market close on Tuesday, October 27, 2020 . In light of the pending transaction with Siemens Healthineers, Varian will not be hosting a confere

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical updates on naxitamab for the treatment of relapsed/refractory high-risk neuroblastoma and omburtamab for CNS/leptomeningeal metastasis from neuroblastoma. Data was presented at the Interna

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that two of its employees have received top honors from Cardinal Health for their outstanding service and performance for the previous year. Brad Leonard ,

Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today the FDA approval of its new CardioGen-82 infusion system to enhance automation,

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird Global Industrial Conference, which is being held virtually, on Wednesday, November 11, 2020. About Novanta Novanta is a leading gl

Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in China by the National Medical Products Administration